@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAjZFZy9u_M7OYUKg216Ze5c5iKU7krKAAapw7fVjdRCI> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAjZFZy9u_M7OYUKg216Ze5c5iKU7krKAAapw7fVjdRCI#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix chebi: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=> .
@prefix go: <http://amigo.geneontology.org/amigo/term/GO:> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix hasAgent: <http://semanticscience.org/resource/SIO_000139> .
@prefix mesh: <http://purl.bioontology.org/ontology/MSH/> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 hasAgent: sub:_2;
    a go:0016301 .
  
  sub:_2 geneProductOf: hgnc:3236;
    a Protein: .
  
  sub:_3 occursIn: mesh:D001940, species:9606;
    rdf:object sub:_1;
    rdf:predicate belv:directlyDecreases;
    rdf:subject chebi:49668;
    a rdf:Statement .
  
  sub:assertion rdfs:label "a(CHEBI:gefitinib) =| kin(p(HGNC:EGFR))" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_5;
    pav:version "1.4" .
  
  sub:_4 prov:value "Table 1 Small molecule inhibitors of ErbB tyrosine kinases in clinical development EGFR IC50 HER2 IC50 HER4 IC50 Agent (umol/l) (umol/l) (umol/l) Reversible/irreversible Source Gefitinib (Iressa, ZD1839) 0.02 3.7 NR Reversible AstraZeneca Erlotinib (Tarceva, OSI-774) 0.02 3.5 NR Reversible Genentech/Roche EKB-569 0.038 1.2 NR Irreversible Wyeth-Ayerst TAK-165 NR 0.006 NR NR Takeda GW572016 0.011 0.009 NR Reversible GlaxoSmithKline PKI-166 0.02 0.1 NR Reversible Novartis AEE-788 0.002 0.006 0.16 Reversible Novartis CI-1033 0.0008 0.019 0.007 Irreversible Pfizer AEE-788 also inhibits KDR with a 50% inhibitory concentration (IC50) of 0.077 umol/l. NR, not reported. EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor.";
    prov:wasQuotedFrom pubmed:15318926 .
  
  sub:_5 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:15318926;
    prov:wasDerivedFrom beldoc:, sub:_4 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:30:27.019+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}